Mizuho Securities analyst Difei Yang maintained a Buy rating on Akebia Therapeutics (AKBA) today and set a price target of $17. The company’s shares closed yesterday at $8.43.
Yang said:
“We expect Akebia to compete with two other products within next-generation (HIF-PHI) anemia drugs and we believe order of market entry will be; 1) Fibrogen (FGEN, Buy, $74 PT)’s roxadustat, 2) Akebia’s vadadustat, and 3) GlaxoSmithKline (GSK, Not-rated)’s daprodustat, which we think is ~ 6 months behind vadadustat.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.7% and a 48.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
Akebia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $13.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.03 and a one-year low of $6.68. Currently, Akebia Therapeutics has an average volume of 574.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for hypoxia-inducible factor. It also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders.
